ABIVAX Société Anonyme (AAVXF)
USD 5.81
(0.0%)
USD 5.81
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.91 Million EUR | -12.5% |
| 2022 | 4.47 Million EUR | 3858.82% |
| 2021 | -119 Thousand EUR | -291.94% |
| 2020 | 62 Thousand EUR | 785.71% |
| 2019 | 7000.00 EUR | 114.0% |
| 2018 | -50 Thousand EUR | -733.33% |
| 2017 | -6000.00 EUR | -107.41% |
| 2016 | 81 Thousand EUR | 126.73% |
| 2015 | -303 Thousand EUR | -38.13% |
| 2014 | -219.36 Thousand EUR | -154.73% |
| 2013 | -86.11 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 3.39 Million EUR | 0.0% |
| 2024 Q1 | 3.39 Million EUR | 355.74% |
| 2023 Q3 | 1.12 Million EUR | 41.19% |
| 2023 FY | 3.91 Million EUR | -12.5% |
| 2023 Q1 | 1.12 Million EUR | 2.93% |
| 2023 Q2 | 795 Thousand EUR | -29.27% |
| 2023 Q4 | 744.5 Thousand EUR | -33.67% |
| 2022 Q3 | 1.12 Million EUR | 4.56% |
| 2022 FY | 4.47 Million EUR | 3858.82% |
| 2022 Q4 | 1.09 Million EUR | -2.85% |
| 2022 Q2 | 1.07 Million EUR | -3.5% |
| 2022 Q1 | 1.11 Million EUR | -72.69% |
| 2021 Q4 | 4.07 Million EUR | -64.12% |
| 2021 Q1 | -11.36 Million EUR | -43626.92% |
| 2021 Q2 | -32 Thousand EUR | 99.72% |
| 2021 FY | -119 Thousand EUR | -291.94% |
| 2021 Q3 | 11.36 Million EUR | 35628.13% |
| 2020 Q4 | -26 Thousand EUR | 99.75% |
| 2020 Q2 | -33 Thousand EUR | 99.5% |
| 2020 Q3 | -10.3 Million EUR | -31127.27% |
| 2020 Q1 | -6.57 Million EUR | -11147.01% |
| 2020 FY | 62 Thousand EUR | 785.71% |
| 2019 Q3 | -6.8 Million EUR | -27124.0% |
| 2019 Q4 | -58.5 Thousand EUR | 99.14% |
| 2019 FY | 7000.00 EUR | 114.0% |
| 2019 Q1 | -7.29 Million EUR | -78.41% |
| 2019 Q2 | -25 Thousand EUR | 99.66% |
| 2018 FY | -50 Thousand EUR | -733.33% |
| 2018 Q3 | -4.08 Million EUR | -27.98% |
| 2018 Q2 | -3.19 Million EUR | 0.0% |
| 2018 Q1 | -3.19 Million EUR | -34.66% |
| 2018 Q4 | -4.08 Million EUR | 0.0% |
| 2017 Q1 | -2.68 Million EUR | 8.56% |
| 2017 Q2 | -2.68 Million EUR | 0.0% |
| 2017 Q3 | -2.37 Million EUR | 11.73% |
| 2017 Q4 | -2.37 Million EUR | 0.0% |
| 2017 FY | -6000.00 EUR | -107.41% |
| 2016 Q2 | -4.3 Million EUR | 0.0% |
| 2016 FY | 81 Thousand EUR | 126.73% |
| 2016 Q3 | -2.93 Million EUR | 31.82% |
| 2016 Q1 | -4.3 Million EUR | -7.35% |
| 2016 Q4 | -2.93 Million EUR | 0.0% |
| 2015 Q1 | -3.24 Million EUR | -146.43% |
| 2015 Q2 | -3.24 Million EUR | 0.0% |
| 2015 Q3 | -4.01 Million EUR | -23.58% |
| 2015 Q4 | -4.01 Million EUR | 0.0% |
| 2015 FY | -303 Thousand EUR | -38.13% |
| 2014 FY | -219.36 Thousand EUR | -154.73% |
| 2014 Q4 | -1.31 Million EUR | 0.0% |
| 2014 Q2 | -226.5 Thousand EUR | 0.0% |
| 2014 Q1 | -226.5 Thousand EUR | 0.0% |
| 2014 Q3 | -1.31 Million EUR | -481.9% |
| 2013 FY | -86.11 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 11.7 Million USD | 66.564% |
| Arch Therapeutics, Inc. | -2439.00 USD | 160575.605% |
| CSL Limited | 7.56 Billion USD | 99.948% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 96.714% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -2116.81% |
| BioStem Technologies, Inc. | 15.42 Million USD | 74.625% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 59.276% |
| Qrons Inc. | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 1325.012% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 115.172% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -5491.429% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 3250.075% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 8210.404% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -2685.765% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.044% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 73.905% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -126076.66% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 60.037% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -5854.844% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 11561.201% |
| Mesoblast Limited | -35.16 Million USD | 111.129% |
| Marizyme, Inc. | 457.7 Thousand USD | -755.142% |
| Genus plc | 178.7 Million USD | 97.81% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 98.222% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -6189.975% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -854.25% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 35681.818% |
| ContraFect Corporation | -154 Thousand USD | 2641.558% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 7928.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -4998.943% |
| IMV Inc. | -962.29 Thousand USD | 506.735% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 1110.062% |
| MultiCell Technologies, Inc. | 49.32 USD | -7935828.629% |
| ONE Bio Corp. | 20.12 Million USD | 80.552% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 90.279% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -7904.09% |
| Q BioMed Inc. | -8988.00 USD | 43646.951% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 86.148% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 25476.037% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 91.176% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 442.861% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 79138.772% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 4113.741% |
| GB Sciences, Inc. | -624.00 USD | 627343.59% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 4649.681% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 1881830.769% |
| Enzolytics Inc. | 30.7 Thousand USD | -12645.864% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -711.304% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.647% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 860.724% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -533.965% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 44296.025% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 4767.915% |
| Kadimastem Ltd | -630.13 Thousand USD | 721.134% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -296.161% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 33171.398% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -2116.81% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -188.4% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 13596.552% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -769.695% |
| SYBLEU INC | 11.69 Thousand USD | -33364.432% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 15.061% |
| Bioxytran, Inc. | -8285.00 USD | 47342.004% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 1149.33% |
| Neutra Corp. | 14.33 Thousand USD | -27203.802% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 4873.171% |
| PureTech Health plc | -1.6 Million USD | 344.167% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 490.917% |
| IXICO plc | 3.27 Million USD | -19.694% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 663.977% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 318.537% |
| CSL Limited | 7.7 Billion USD | 99.949% |
| Cellectis S.A. | 18 Thousand USD | -21644.444% |